Ellison Medical Institute and UniQuest enter exclusive license to advance novel prostate cancer therapy toward first-in-human studies

LOS ANGELES, June 22, 2026 /PRNewswire/ -- The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The University of Queensland (UQ), to advance QED-203, a promising new treatment for advanced and therapy-resistant prostate...